Related Experiment Video

Updated: Jul 4, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Immunotherapy of pancreatic carcinoma

Angela Märten1, Markus W Büchler

  • 1University of Heidelberg, Department of Surgery, Im Neuenheimer Feld 110, Heidelberg 69120, Germany. angela.maerten@med.uni-heidelberg.de

Current Opinion in Investigational Drugs (London, England : 2000)
|June 3, 2008
PubMed

Insights

Immunotherapy shows promise for treating pancreatic cancer, a disease with a poor prognosis. Further phase III trials are needed to confirm its effectiveness in combination therapies with immunomonitoring.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Pancreatic cancer (pancreatic adenocarcinoma) has a particularly poor prognosis due to its systemic nature and resistance to conventional treatments like radiotherapy and chemotherapy.
  • Immunotherapy presents a promising therapeutic avenue for pancreatic cancer, with ongoing research exploring its potential.

Purpose of the Study:

  • To review the current status and future directions of immunotherapy for pancreatic adenocarcinoma.
  • To highlight the need for rigorous investigation of immunotherapy, particularly in combination therapies, through phase III clinical trials.

Main Methods:

  • Review of existing phase I/II clinical trial data on immunotherapy for pancreatic cancer.
  • Analysis of results from unspecific stimulation and peptide vaccination strategies.
  • Evaluation of promising data from phase II combination therapy trials.

Main Results:

  • Encouraging outcomes have been observed with unspecific immune stimulation and peptide vaccinations.
  • Phase II clinical trials involving combination therapies that include immunotherapy show highly promising results.

Conclusions:

  • Immunotherapy is a viable and promising treatment strategy for pancreatic adenocarcinoma.
  • Phase III randomized controlled trials incorporating immunomonitoring are essential to validate the efficacy of immunotherapy and combination therapies for pancreatic cancer.

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...